Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trialsD. Ross Camidge, Sanjay Popat, Myung‐Ju Ahn et al.|Lung Cancer|2025Cited by 3
PPD01.01 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-treated MET exon 14 (METex14) Skipping NSCLC in the VISION TrialXiuning Le, Paul K. Paik, Marina Chiara Garassino et al.|Journal of Thoracic Oncology|2024Cited by 0